Mednet Logo
Community

In what clinical scenarios do you utilize venetoclax-based therapy in relapsed/refractory multiple myeloma?

Venetoclax has demonstrated efficacy in patients harboring t(11;14) mutations but is not FDA approved for MM. Can you expand on what situations you may recommend this? What is your preferred dosing schedule/timing? Or combination therapy?
Community PollStarted

What ven combination would you use in the appropriate RRMM setting?

14 physicians have voted

Join Mednetto vote and see how they answered.

3 Answers
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Winship Cancer Institute of Emory University
Answered on

I would caution that there is no strong data that the combination of Venetoclax with a proteasome inhibitor or a CD38 antibody makes sense; in fact, the addition is more likely than not to cause harm.

Adding on to Venetoclax in patients that are naive to proteasome inhibitor or CD38 Ab naive is jus...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Chicago
Answered on

Disclaimer, before I comment, is that venetoclax is not FDA approved for myeloma and any use is off-label. The results for those with t(11;14) or high BCL2 expression are promising, but the phase 3 BELLINI study of Ven-Vd vs Vd showed inferior OS for Ven-Vd. This was mostly due to infection risk. So...

Join for free or sign in to see the full answer

Mednet Member
Mednet MemberInvited Expert
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center
Answered on · Updated on

Excellent question. Others (@Dr. First Last and @Dr. First Last) had answered several of these subquestions in a prior thread here:

https://www.themednet.org/question/10770.

But we didn't fully address the ideal combo regimen to use in the appropriate setting - e.g., t(11;14) still present by FISH [BC...

Join for free or sign in to see the full answer